Lipoprotein(a) and cardiovascular disease in heterozygous familial hypercholesterolemia: Should we also blame the LDL receptor?

Journal of the American College of Cardiology

Volumn 63, Issue 19, 2014, Pages 1990-1991

  Santos, Raul D ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

cardiovascular disease; familial hypercholesterolemia LDL receptor; lipoprotein(a)

Indexed keywords

APOLIPOPROTEIN A; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; KEXIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SUBTILISIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN RECEPTOR;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CATABOLISM; CHOLESTEROL BLOOD LEVEL; DISEASE SEVERITY; EVIDENCE BASED MEDICINE; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; HYPERTENSION; INCIDENCE; LIPOPROTEIN BLOOD LEVEL; MUTATIONAL ANALYSIS; NONHUMAN; NOTE; PREVALENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; RISK FACTOR; SMOKING; DISEASE ASSOCIATION; EDITORIAL; GENE EXPRESSION; GENE INTERACTION; GENE MUTATION; HETEROZYGOSITY; HIGH RISK POPULATION; LDLR GENE; LIPOPROTEIN METABOLISM; PATHOGENESIS; SURVIVAL TIME;

CARDIOVASCULAR DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA-LDL RECEPTOR; LIPOPROTEIN(A);

CARDIOVASCULAR DISEASES; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEIN(A); MALE; MUTATION; RECEPTORS, LDL;

EID: 84900542778     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.12.049     Document Type: Editorial

References (17)

1. B.G. Nordestgaard, M.J. Chapman, and S.E. Humphries et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society Eur Heart J 34 2013 3478 3490
2. M. Seed, F. Hoppichler, and D. Reaveley et al. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia N Engl J Med 322 1990 1494 1499
3. A.C. Jansen, E.S. van Aalst-Cohen, and M.W. Tanck et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients J Intern Med 256 2004 482 490
4. P.N. Hopkins, S. Stephenson, L.L. Wu, W.A. Riley, Y. Xin, and S.C. Hunt Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia Am J Cardiol 87 2001 547 553
5. M.H. Miname, M.S. Ribeiro II, and J. Parga Filho et al. Evaluation of subclinical atherosclerosis by computed tomography coronary angiography and its association with risk factors in familial hypercholesterolemia Atherosclerosis 213 2010 486 491
6. Emerging Risk Factors Collaboration Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality JAMA 302 2009 412 423
7. P.R. Kamstrup, A. Tybjaerg-Hansen, R. Steffensen, and B.G. Nordestgaard Genetically elevated lipoprotein(a) and increased risk of myocardial infarction JAMA 301 2009 2331 2339
8. M.A. Hancock, M.B. Boffa, S.M. Marcovina, M.E. Nesheim, and M.L. Koschinsky Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces J Biol Chem 278 2003 23260 23269
9. S. Tsimikas, and J.L. Witztum The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity Curr Opin Lipidol 19 2008 369 377
10. D.J. Rader, W. Cain, and K. Ikewaki et al. The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate J Clin Invest 93 1994 2758 2763
11. W.J. Cain, J.S. Millar, and A.S. Himebauch et al. Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a] J Lipid Res 46 2005 2681 2691
12. R. Alonso, E. Andres, N. Mata for the SAFEHEART Investigators Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation J Am Coll Cardiol 63 2014 1982 1989
13. B.G. Nordestgaard, M.J. Chapman, and K. Ray et al. Lipoprotein(a) as a cardiovascular risk factor: current status Eur Heart J 31 2010 2844 2853
14. H.G. Kraft, A. Lingenhel, F.J. Raal, M. Hohenegger, and G. Utermann Lipoprotein(a) in homozygous familial hypercholesterolemia Arterioscler Thromb Vasc Biol 20 2000 522 528
15. F. Raal, R. Scott, and R. Somaratne et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial Circulation 126 2012 2408 2417
16. J. Leebmann, E. Roeseler, and U. Julius et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)- hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study Circulation 128 2013 2567 2576
17. F.J. Raal, R.D. Santos, and D.J. Blom et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial Lancet 375 2010 998 1006